Zentalis Pharmaceuticals' Azenosertib Set for Key Milestones in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Progress: Zentalis has completed enrollment in the DENALI Part 2a trial for Azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, with dose confirmation expected in 1H 2026 and topline data by year-end, potentially supporting accelerated FDA approval.
- Market Demand: Cyclin E1-positive platinum-resistant ovarian cancer accounts for about half of all PROC cases, with patients facing limited treatment options and poor outcomes, making Azenosertib's development crucial to address this significant unmet medical need.
- New Trial Initiation: Zentalis plans to initiate the ASPENOVA Phase 3 randomized confirmatory trial in 1H 2026, running concurrently with DENALI Part 2, to compare Azenosertib with standard chemotherapy, further validating its clinical value.
- Stock Performance: ZNTL shares have traded between $1.01 and $3.06 over the past year, closing yesterday at $1.78, up 29.92%, and further rising to $1.83 in after-hours trading, reflecting positive market sentiment regarding its future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZNTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZNTL
Wall Street analysts forecast ZNTL stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.140
Low
4.00
Averages
6.60
High
10.00
Current: 4.140
Low
4.00
Averages
6.60
High
10.00
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zentalis Drug Shows Promising Results in Ovarian Cancer Clinical Trial
- Clinical Trial Results: In a clinical trial for ovarian cancer, Zentalis's WEE1 inhibitor azenosertib combined with paclitaxel demonstrated a 39% overall response rate (ORR) and a median progression-free survival (PFS) of 7.3 months, indicating the potential of this combination in treating resistant ovarian cancer.
- Optimal Dose Discovery: The 250 mg intermittent dose cohort showed a 50% ORR and a median duration of response (DOR) of 9.2 months, suggesting this dose may represent the optimal therapeutic combination, further supporting the drug's application prospects in ovarian and other tumor types.
- Safety Analysis: Among 46 patients, a low frequency of high-grade adverse events was observed, with the most common treatment-related adverse events being fatigue (60.9%) and anemia (58.7%), indicating a favorable safety profile for further clinical use.
- Future Research Directions: The results from the MUIR trial will provide crucial data support for Zentalis's registration trials in ovarian cancer, particularly in Cyclin E1-positive patients, further advancing the clinical development and market potential of the drug.
See More
Zentalis Pharmaceuticals Reports Encouraging Phase 1b Results for Azenosertib
- Clinical Trial Results: Zentalis Pharmaceuticals announced preliminary results from the MUIR trial, indicating Azenosertib's potential in treating platinum-resistant ovarian cancer, with results to be presented at the 2026 ASCO Annual Meeting, which could further propel the company's growth in the biopharmaceutical sector.
- Efficacy Assessment: The Overall Response Rate (ORR) for Azenosertib combined with Paclitaxel was 50.0%, significantly higher than the 39.1% across all dose cohorts, suggesting the drug's effectiveness in a specific patient population, potentially attracting more investor interest.
- Safety Analysis: Although approximately 20% of patients experienced serious Treatment-Related Adverse Events (TRAEs), Azenosertib demonstrated a manageable safety profile with relatively low rates of high-grade adverse events, laying a foundation for its future clinical applications.
- Market Reaction: Zentalis Pharmaceuticals' shares closed up 11.59% at $4.14 on Thursday, reflecting a positive market response to its clinical trial results, which may support the company's future financing and research efforts.
See More
Zentalis Pharmaceuticals Q1 Earnings Miss Expectations
- Earnings Report Shortfall: Zentalis Pharmaceuticals reported a Q1 GAAP EPS of -$0.50, missing expectations by $0.03, indicating challenges in profitability that may affect investor confidence.
- Declining Cash Reserves: As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $211.8 million, down from $245.9 million as of December 31, 2025, reflecting pressure on financial management.
- Sufficient Funding Assessment: Zentalis believes that its cash reserves as of March 31, 2026, will be adequate to fund its operating expenses and capital expenditures into late 2027, indicating short-term financial stability.
- Future Outlook: Despite the current financial shortfall, Zentalis maintains an optimistic view for the future, believing that existing funds will support its R&D and operations, potentially safeguarding subsequent product development.
See More
Zentalis Grants Stock Options to New Employee
- Stock Option Grant: On May 1, 2026, Zentalis granted 26,000 non-qualified stock options to a new employee, aimed at attracting talent and enhancing the company's competitive edge.
- Incentive Plan Context: The stock options were granted under the 2022 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), specifically designed to incentivize new hires to join the company.
- Option Exercise Price: The exercise price of the stock options is set at $4.09 per share, matching the closing price of Zentalis' common stock on the grant date, ensuring employees receive fair market value.
- Vesting Arrangement: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, ensuring employee retention and loyalty through continued service to Zentalis.
See More
Zentalis' Azenosertib Accepted for ASCO Presentation
- ASCO Recognition: Zentalis announced that its abstract on the WEE1 inhibitor azenosertib for ovarian cancer has been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5, 2026, highlighting the company's ongoing innovation in clinical oncology.
- MUIR Trial Progress: Data from Part 1 of the MUIR trial will showcase the efficacy of azenosertib in combination with paclitaxel, particularly in platinum-resistant ovarian cancer patients, expected to provide crucial evidence for the drug's potential application across various tumor types and further propel its clinical development.
- Clinical Trial Design: The MUIR trial is a multi-part, open-label Phase 1b clinical trial primarily assessing safety and tolerability, with key secondary objectives including objective response rate and progression-free survival, demonstrating Zentalis' rigor and foresight in clinical research.
- Market Potential: Azenosertib, as the first treatment targeting Cyclin E1-positive platinum-resistant ovarian cancer, is in late-stage development and has received Fast Track Designation from the FDA, expected to fill a significant treatment gap for this specific patient population, indicating substantial market prospects.
See More
Zentalis Unveils New Data, Paving New Directions in Cancer Treatment
- Preclinical Data Highlights: Zentalis presented preclinical data at the AACR meeting showing that combinations of azenosertib with antibody-drug conjugates can induce complete tumor responses in models resistant to ADCs, indicating potential applications beyond ovarian cancer and opening new avenues for pipeline expansion.
- Significant Preclinical Efficacy: In a model resistant to the approved TOPO1i ADC, the combination of azenosertib and enfortumab vedotin achieved complete responses in 87.5% of mice, effectively preventing tumor progression even after treatment cessation, showcasing its potential in treating resistant tumors.
- Real-World Data Validation: The real-world data presented at AACR highlight that Cyclin E1-positive ovarian cancer patients face significantly worse clinical outcomes with standard therapies, underscoring the importance of azenosertib for this population and potentially supporting the upcoming DENALI and ASPENOVA studies.
- Strong Market Demand: Cyclin E1-positive patients had an average time to next treatment of 13.2 months post-first-line therapy, significantly lower than the 19.5 months for Cyclin E1-negative patients, emphasizing the urgent need for targeted therapies in this specific population and driving the clinical development of azenosertib.
See More
Zentalis Drug Shows Promising Results in Ovarian Cancer Clinical Trial
- Clinical Trial Results: In a clinical trial for ovarian cancer, Zentalis's WEE1 inhibitor azenosertib combined with paclitaxel demonstrated a 39% overall response rate (ORR) and a median progression-free survival (PFS) of 7.3 months, indicating the potential of this combination in treating resistant ovarian cancer.
- Optimal Dose Discovery: The 250 mg intermittent dose cohort showed a 50% ORR and a median duration of response (DOR) of 9.2 months, suggesting this dose may represent the optimal therapeutic combination, further supporting the drug's application prospects in ovarian and other tumor types.
- Safety Analysis: Among 46 patients, a low frequency of high-grade adverse events was observed, with the most common treatment-related adverse events being fatigue (60.9%) and anemia (58.7%), indicating a favorable safety profile for further clinical use.
- Future Research Directions: The results from the MUIR trial will provide crucial data support for Zentalis's registration trials in ovarian cancer, particularly in Cyclin E1-positive patients, further advancing the clinical development and market potential of the drug.
See More
Zentalis Pharmaceuticals Reports Encouraging Phase 1b Results for Azenosertib
- Clinical Trial Results: Zentalis Pharmaceuticals announced preliminary results from the MUIR trial, indicating Azenosertib's potential in treating platinum-resistant ovarian cancer, with results to be presented at the 2026 ASCO Annual Meeting, which could further propel the company's growth in the biopharmaceutical sector.
- Efficacy Assessment: The Overall Response Rate (ORR) for Azenosertib combined with Paclitaxel was 50.0%, significantly higher than the 39.1% across all dose cohorts, suggesting the drug's effectiveness in a specific patient population, potentially attracting more investor interest.
- Safety Analysis: Although approximately 20% of patients experienced serious Treatment-Related Adverse Events (TRAEs), Azenosertib demonstrated a manageable safety profile with relatively low rates of high-grade adverse events, laying a foundation for its future clinical applications.
- Market Reaction: Zentalis Pharmaceuticals' shares closed up 11.59% at $4.14 on Thursday, reflecting a positive market response to its clinical trial results, which may support the company's future financing and research efforts.
See More
Zentalis Pharmaceuticals Q1 Earnings Miss Expectations
- Earnings Report Shortfall: Zentalis Pharmaceuticals reported a Q1 GAAP EPS of -$0.50, missing expectations by $0.03, indicating challenges in profitability that may affect investor confidence.
- Declining Cash Reserves: As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $211.8 million, down from $245.9 million as of December 31, 2025, reflecting pressure on financial management.
- Sufficient Funding Assessment: Zentalis believes that its cash reserves as of March 31, 2026, will be adequate to fund its operating expenses and capital expenditures into late 2027, indicating short-term financial stability.
- Future Outlook: Despite the current financial shortfall, Zentalis maintains an optimistic view for the future, believing that existing funds will support its R&D and operations, potentially safeguarding subsequent product development.
See More
Zentalis Grants Stock Options to New Employee
- Stock Option Grant: On May 1, 2026, Zentalis granted 26,000 non-qualified stock options to a new employee, aimed at attracting talent and enhancing the company's competitive edge.
- Incentive Plan Context: The stock options were granted under the 2022 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4), specifically designed to incentivize new hires to join the company.
- Option Exercise Price: The exercise price of the stock options is set at $4.09 per share, matching the closing price of Zentalis' common stock on the grant date, ensuring employees receive fair market value.
- Vesting Arrangement: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, ensuring employee retention and loyalty through continued service to Zentalis.
See More
Zentalis' Azenosertib Accepted for ASCO Presentation
- ASCO Recognition: Zentalis announced that its abstract on the WEE1 inhibitor azenosertib for ovarian cancer has been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5, 2026, highlighting the company's ongoing innovation in clinical oncology.
- MUIR Trial Progress: Data from Part 1 of the MUIR trial will showcase the efficacy of azenosertib in combination with paclitaxel, particularly in platinum-resistant ovarian cancer patients, expected to provide crucial evidence for the drug's potential application across various tumor types and further propel its clinical development.
- Clinical Trial Design: The MUIR trial is a multi-part, open-label Phase 1b clinical trial primarily assessing safety and tolerability, with key secondary objectives including objective response rate and progression-free survival, demonstrating Zentalis' rigor and foresight in clinical research.
- Market Potential: Azenosertib, as the first treatment targeting Cyclin E1-positive platinum-resistant ovarian cancer, is in late-stage development and has received Fast Track Designation from the FDA, expected to fill a significant treatment gap for this specific patient population, indicating substantial market prospects.
See More
Zentalis Unveils New Data, Paving New Directions in Cancer Treatment
- Preclinical Data Highlights: Zentalis presented preclinical data at the AACR meeting showing that combinations of azenosertib with antibody-drug conjugates can induce complete tumor responses in models resistant to ADCs, indicating potential applications beyond ovarian cancer and opening new avenues for pipeline expansion.
- Significant Preclinical Efficacy: In a model resistant to the approved TOPO1i ADC, the combination of azenosertib and enfortumab vedotin achieved complete responses in 87.5% of mice, effectively preventing tumor progression even after treatment cessation, showcasing its potential in treating resistant tumors.
- Real-World Data Validation: The real-world data presented at AACR highlight that Cyclin E1-positive ovarian cancer patients face significantly worse clinical outcomes with standard therapies, underscoring the importance of azenosertib for this population and potentially supporting the upcoming DENALI and ASPENOVA studies.
- Strong Market Demand: Cyclin E1-positive patients had an average time to next treatment of 13.2 months post-first-line therapy, significantly lower than the 19.5 months for Cyclin E1-negative patients, emphasizing the urgent need for targeted therapies in this specific population and driving the clinical development of azenosertib.
See More
